BACKGROUND: Fractional dose (one-fifth of full intramuscular dose) of inactivated poliovirus vaccine (fIPV) administered intradermally is used as IPV dose-sparing strategy. We compared the rate of decline of poliovirus antibodies (PVA) in recipients of 2 doses of fIPV or IPV. METHODS: A community-based randomized controlled trial was conducted in Karachi, Pakistan. Children aged 14 weeks were randomized into fIPV or full IPV (study arms A, B) and received 1 vaccine dose at age 14 weeks and 1 at age 9 months. PVAs were measured at age 14, 18 weeks and 10, 21 months. RESULTS: Seroprevalence of poliovirus type 2 antibodies in 170/250 (68%) children after 2 IPV or fIPV doses at age 10 months in A and B reached 100% vs 99% (P = .339), and at 21 months, 86% vs 67% (P = .004). Between age 10 and 21 months antibody log2 titers dropped from ≥ 10.5 to 6.8 in A and from 9.2 to 3.7 in B. CONCLUSIONS: There was a significant decline in antibody titers 12 months following the second IPV dose. The slope of decline was similar for full IPV and fIPV recipients. The results provide further evidence that fIPV is a viable option for IPV dose-sparing. CLINICAL TRIALS REGISTRATION: NCT03286803.
BACKGROUND: Fractional dose (one-fifth of full intramuscular dose) of inactivated poliovirus vaccine (fIPV) administered intradermally is used as IPV dose-sparing strategy. We compared the rate of decline of poliovirus antibodies (PVA) in recipients of 2 doses of fIPV or IPV. METHODS: A community-based randomized controlled trial was conducted in Karachi, Pakistan. Children aged 14 weeks were randomized into fIPV or full IPV (study arms A, B) and received 1 vaccine dose at age 14 weeks and 1 at age 9 months. PVAs were measured at age 14, 18 weeks and 10, 21 months. RESULTS: Seroprevalence of poliovirus type 2 antibodies in 170/250 (68%) children after 2 IPV or fIPV doses at age 10 months in A and B reached 100% vs 99% (P = .339), and at 21 months, 86% vs 67% (P = .004). Between age 10 and 21 months antibody log2 titers dropped from ≥ 10.5 to 6.8 in A and from 9.2 to 3.7 in B. CONCLUSIONS: There was a significant decline in antibody titers 12 months following the second IPV dose. The slope of decline was similar for full IPV and fIPV recipients. The results provide further evidence that fIPV is a viable option for IPV dose-sparing. CLINICAL TRIALS REGISTRATION: NCT03286803.
Authors: Concepción F Estívariz; Hamid Jafari; Roland W Sutter; T Jacob John; Vibhor Jain; Ashutosh Agarwal; Harish Verma; Mark A Pallansch; Ajit P Singh; Sherine Guirguis; Jitendra Awale; Anthony Burton; Sunil Bahl; Arani Chatterjee; R Bruce Aylward Journal: Lancet Infect Dis Date: 2011-11-07 Impact factor: 25.071
Authors: Frithjofna Abbink; Anne M Buisman; Gerda Doornbos; Jan Woldman; Tjeerd G Kimman; Marina A E Conyn-van Spaendonck Journal: J Infect Dis Date: 2005-02-10 Impact factor: 5.226
Authors: Ali Jafer Mohammed; Salah AlAwaidy; Shyam Bawikar; Padmamohan J Kurup; Emadaldin Elamir; Mahmoud M A Shaban; Sharif M Sharif; Harrie G A M van der Avoort; Mark A Pallansch; Pradeep Malankar; Anthony Burton; Meghana Sreevatsava; Roland W Sutter Journal: N Engl J Med Date: 2010-06-24 Impact factor: 91.245
Authors: Dang Thi Thanh Huyen; Ondrej Mach; Nguyen Thanh Trung; Pham Quang Thai; Ho Vinh Thang; William C Weldon; M Steven Oberste; Visalakshi Jeyaseelan; Roland W Sutter; Dang Duc Anh Journal: J Infect Dis Date: 2019-07-02 Impact factor: 7.759
Authors: Deepa Gamage; Ondrej Mach; Samitha Ginige; William C Weldon; M Steven Oberste; Visalakshi Jeyaseelan; Roland W Sutter Journal: J Infect Dis Date: 2019-05-24 Impact factor: 7.759
Authors: Siddhartha Kumar Bhaumik; Raveendra R Kulkarni; William C Weldon; Eduardo L V Silveira; Hasan Ahmed; Sivaram Gunisetty; Anmol Chandele; Rustom Antia; Harish Verma; Roland Sutter; Mark A Pallansch; M Steven Oberste; Francois Villinger; Walter Orenstein; Kaja Murali-Krishna Journal: Clin Infect Dis Date: 2018-10-30 Impact factor: 9.079
Authors: Asma B Aziz; Harish Verma; Visalakshi Jeyaseelan; Mohammad Yunus; Samarea Nowrin; Deborah D Moore; Bernardo A Mainou; Ondrej Mach; Roland W Sutter; Khalequ Zaman Journal: J Infect Dis Date: 2022-10-17 Impact factor: 7.759
Authors: Gabriel Trueba; Vishali Jeyaseelan; Lazaro Lopez; Bernardo A Mainou; Yiting Zhang; Alvaro Whittembury; Alfredo Jose Olmedo Valarezo; Gonzalo Baquero; Rosa Romero de Aguinaga; Lucia Jeannete Zurita Salinas; Maria Gabriela Santacruz Mancheno; Diana Elizabeth Medina Chacho; Emmanuelle Quentin; Ana Elena Chevez; Gloria Rey-Benito; Ondrej Mach Journal: Lancet Reg Health Am Date: 2022-07